EXEL (US) share price forecast & AI signal — Exelixis, Inc
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in EXEL
Exelixis, Inc is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a SELL with low confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About Exelixis, Inc
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO,...
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $69.57 |
| 2026-11-05 | $68.71 |
| 2026-11-04 | $72.75 |
| 2026-11-03 | $72.31 |
| 2026-11-02 | $70.13 |
| 2026-10-30 | $69.39 |
| 2026-10-29 | $66.20 |
EXEL FAQ
Is Exelixis, Inc (EXEL) a buy or sell this week?
The ACE Stock Bots machine-learning model rates EXEL a SELL for the week of 2026-10-30 with low confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for EXEL?
Every week the model scores EXEL across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.